The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 21, 2021

Filed:

Dec. 07, 2017
Applicant:

Gary E. Borodic, Canton, MA (US);

Inventor:

Gary E. Borodic, Canton, MA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 27/02 (2006.01); C07K 16/22 (2006.01); C07K 14/33 (2006.01); A61K 38/48 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 38/4893 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 27/02 (2018.01); C07K 16/22 (2013.01); C07K 2317/24 (2013.01);
Abstract

Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins). In some embodiments, the disclosed formulations also include one or more anti-VEGF agents. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may be transported to the intra-ocular region of the patient via axoplasmic transport, thereby allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, allowing for improved therapeutic safety by eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness associated with direct injection into the eye.


Find Patent Forward Citations

Loading…